Evidence map›Paper›PMID 39318989›Full record

ReviewJournal of vitreoretinal diseases

Extended Intraocular Drug-Delivery Platforms for the Treatment of Retinal and Choroidal Diseases.

Charles C Wykoff, Baruch D Kuppermann, Carl D Regillo, Margaret Chang, Seenu M Hariprasad, Jay S Duker, Syed Altaf, Saïd Saïm

Abstract readReview
In one paragraph

Review in Journal of vitreoretinal diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Ranibizumab port delivery system for neovascular age-related macular degeneration: Current evidence and surgical considerations.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. From the Editor-in-Chief.Journal of vitreoretinal diseases
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Charles C WykoffRetina Consultants of Texas; Retina Consultants of America; Blanton Eye Institute, Houston, Methodist Hospital, Houston, TX, USA.ORCID https://orcid.org/0000-0001-7756-5091
Baruch D KuppermannGavin Herbert Eye Institute, University of California, Irvine, CA, USA.
Carl D RegilloMid Atlantic Retina, Wills Eye Hospital Retina Service, Thomas Jefferson University, Philadelphia, PA, USA.
Margaret ChangRetinal Consultants Medical Group, Sacramento, CA, USA.
Seenu M HariprasadUniversity of Chicago, Department of Ophthalmology and Visual Science, Chicago, IL, USA.
Jay S DukerEyePoint Pharmaceuticals, Watertown, MA, USA.
Syed AltafEyePoint Pharmaceuticals, Watertown, MA, USA.
Saïd SaïmEyePoint Pharmaceuticals, Watertown, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

drug deliveryintravitrealsustained releasevascular endothelial growth factor

Identifiers

PMID39318989
PMCPMC11418737

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.